Anti-Angiogenic Agents in Pancreatic Cancer: A Review

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 17, 14 Issues, 2017


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
ICCF-CNRS UMR 6296
Université Clermont Auvergne
Clermont-Ferrand
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Anti-Angiogenic Agents in Pancreatic Cancer: A Review



Anti-Cancer Agents in Medicinal Chemistry, 11(5): 464-469.

Author(s): Murwarid M. Assifi and Oscar J Hines.

Affiliation: Department of Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA, 90095-6904, USA.

Abstract

Pancreatic cancer is the fourth leading cause of cancer related death in the United States, with a 5-year survival of less than five percent. Since the majority of patients have locally advanced or metastatic disease at the time of diagnosis, there has been little progress made to extend survival. For over ten years, chemotherapy with gemcitabine has been standard treatment for those patients with advanced pancreatic cancer, prolonging survival by only 5-6 months. To improve upon this modest benefit, several investigations have explored other strategies aimed at curbing pancreatic cancer growth. Because pancreatic cancer has been found to have a profoundly hypoxic environment with high vascular in-growth, several agents have been developed to target the angiogenesis process. Major emphasis has been placed on anti- vascular endothelial growth factor (VEGF) models and the epidermal growth factor receptor (EGFR) signaling pathway. Over the past several years, a number of phase II and phase III trials have combined gemcitabine with these novel treatments, with the hope of prolonging survival in patients with pancreatic cancer. This review will discuss these therapies and their potential application in a clinical setting.

Keywords:

Pancreatic cancer, angiogenesis.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 11
Issue Number: 5
First Page: 464
Last Page: 469
Page Count: 6
DOI: 10.2174/187152011795677463
Price: $58
Advertisement
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals




Related eBooks



Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science